目的:了解胃癌免疫治疗及疗效预测最新研究进展。方法:检索近年来国内外有关胃癌免疫治疗及疗效预测研究的相关文献并进行综述。结果:胃癌免疫治疗研究最多的是免疫检查点抑制剂,尤其是针对抗程序性细胞死亡蛋白-1 (PD-1)/程序性死亡配...目的:了解胃癌免疫治疗及疗效预测最新研究进展。方法:检索近年来国内外有关胃癌免疫治疗及疗效预测研究的相关文献并进行综述。结果:胃癌免疫治疗研究最多的是免疫检查点抑制剂,尤其是针对抗程序性细胞死亡蛋白-1 (PD-1)/程序性死亡配体-1 (PD-L1)抗体和细胞毒性T淋巴细胞相关抗原4 (CTLA-4抗体)三种类型的研究较多。目前研究火热的免疫PET、CT、MRI和氟脱氧葡萄糖PET的新应用在疗效预测方面都有极大的应用价值。结论:随着免疫治疗研究的深入,胃癌免疫治疗的策略也在不断改进,免疫治疗过程中疗效预测愈发显得重要,针对相应的治疗方法筛选适宜的患者及采用精准治疗手段可进一步让胃癌患者生存获益。Objective: To recognize the latest research progress of gastric cancer immunotherapy and efficacy evaluation. Methods: The domestic and international literature on immunotherapy and efficacy evaluation for GC in recent years were retrieved and reviewed. Results: The most immunotherapy researched was ICIs, especially for programmed death protein-1 (PD-1)/programmed death protein ligand 1 (PD-L1), cytotoxic T lymphocyte associated antigen 4 (CTLA-4 antibody). At present, the new applications of immune PET, CT, MRI and fluorodeoxyglucose PET are of great application value in the efficacy evaluation. Conclusion: With the further study of immunotherapy research, the strategy of immunotherapy for gastric cancer is also constantly improving, and the efficacy evaluation in the process of immunotherapy is becoming more and more important. Screening suitable patients for the corresponding treatment methods and adopting precise treatment methods can further benefit gastric cancer patients.展开更多
文摘目的:了解胃癌免疫治疗及疗效预测最新研究进展。方法:检索近年来国内外有关胃癌免疫治疗及疗效预测研究的相关文献并进行综述。结果:胃癌免疫治疗研究最多的是免疫检查点抑制剂,尤其是针对抗程序性细胞死亡蛋白-1 (PD-1)/程序性死亡配体-1 (PD-L1)抗体和细胞毒性T淋巴细胞相关抗原4 (CTLA-4抗体)三种类型的研究较多。目前研究火热的免疫PET、CT、MRI和氟脱氧葡萄糖PET的新应用在疗效预测方面都有极大的应用价值。结论:随着免疫治疗研究的深入,胃癌免疫治疗的策略也在不断改进,免疫治疗过程中疗效预测愈发显得重要,针对相应的治疗方法筛选适宜的患者及采用精准治疗手段可进一步让胃癌患者生存获益。Objective: To recognize the latest research progress of gastric cancer immunotherapy and efficacy evaluation. Methods: The domestic and international literature on immunotherapy and efficacy evaluation for GC in recent years were retrieved and reviewed. Results: The most immunotherapy researched was ICIs, especially for programmed death protein-1 (PD-1)/programmed death protein ligand 1 (PD-L1), cytotoxic T lymphocyte associated antigen 4 (CTLA-4 antibody). At present, the new applications of immune PET, CT, MRI and fluorodeoxyglucose PET are of great application value in the efficacy evaluation. Conclusion: With the further study of immunotherapy research, the strategy of immunotherapy for gastric cancer is also constantly improving, and the efficacy evaluation in the process of immunotherapy is becoming more and more important. Screening suitable patients for the corresponding treatment methods and adopting precise treatment methods can further benefit gastric cancer patients.
